Latest Regulatory News

Wia Gold has emerged from a pivotal quarter with a 1.95Moz Probable Ore Reserve, A$229.2 million in cash and a proposed US$360 million debt facility supporting its Kokoseb development plan. Construction preparations are advancing, but lender approval, definitive financing documents and Namibian permits remain crucial hurdles before early works can begin.

Critical Resources has secured exclusivity to acquire 90% of a 29 km² Suriname exploration project just 4 km from Zijin’s producing Rosebel mine. The strategic land position expands the company’s prospective Suriname portfolio, but the project has no reported exploration results, resources or reserves.

Rox Resources has accelerated underground development and advanced construction at Youanmi, with the processing plant 39% complete and first gold still targeted for mid-2027. The project is now fully permitted and funded facilities have begun drawing, although construction spending and one major contract remain in focus.

Ramsay Health Care’s proposed separation of its 52.79% Ramsay Santé stake has reached a key regulatory milestone, with ASIC registering the Demerger Booklet. Shareholders will vote on the transaction on 24 November, but approval remains only one step in a process that could create two separately traded healthcare exposures.

Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.

Cobalt Blue has signed a non-binding term sheet with Swiss trader STG Metals for cobalt metal from its proposed Kwinana refinery. The proposed deal covers up to 1,000 tonnes a year, but construction, product qualification and a definitive agreement remain outstanding.

Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.

NOVONIX has replaced a binding PowerCo supply agreement covering at least 32,000 tonnes of synthetic graphite with a framework that leaves volume and price unresolved. A new offtake deal will only be negotiated after customer qualification and further certification.

Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.

Cleanaway has signed a binding scheme implementation deed for EQT Infrastructure to acquire the waste services group for approximately $9.3 billion. Shareholders are being offered $3.095 cash per share, subject to approvals and any dividends paid before completion.

Northern Minerals will not hold its delayed 2025 AGM or 2026 AGM on 25 November after ASIC granted more time amid suspected non-compliance with federal share disposal orders. Both meetings must now be held by 31 March 2027, unless Treasury confirms compliance earlier.

Oceana Metals has completed its acquisition of the Serra Negra rare earths and niobium project in Brazil, turning an exploration proposal into its central operating asset. Four diamond rigs are now drilling toward a maiden JORC resource, although two mining-right amendments and part of the transaction consideration remain unresolved.